Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions
US8765700B2 · kind B2 · utility
1Cited by
2References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 20, 2005 |
| Grant date | Jul 1, 2014 |
| Priority date | — |
| Expiry date | Dec 31, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/346
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin α4 comprising administering to the animal a composition comprising from. 0.001 to 1000 μg per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin α4.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.